Quick Takeaways
- Rubric Capital Management LP filed SCHEDULE 13G for Trevi Therapeutics, Inc. Common Stock, $0.001 par value per share (TRVI).
- Disclosed ownership: 7.1%.
- Date of event: 30 Jun 2025.
Rubric Capital Management LP - 30 Jun 2025 SCHEDULE 13G Report for Trevi Therapeutics, Inc. Common Stock, $0.001 par value per share (TRVI)
- Filing Manager
- Rubric Capital Management LP
- Reporting Manager
- Rubric Capital Management LP
- Symbol
- TRVI
- Shares outstanding
- 119,829,494 shares
- Disclosed Ownership
- 8,531,860 shares
- Ownership
- 7.1%
- Form type
- SCHEDULE 13G
- Filing time
- 09 Jul 2025, 16:06:02 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 13 Feb 2025
- Next filing
- 13 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Rubric Capital Management LP disclosed 7.1% ownership in Trevi Therapeutics, Inc. Common Stock, $0.001 par value per share (TRVI) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 13 Feb 2025.
- Current filing was accepted on 09 Jul 2025, 16:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Rubric Capital Management LP | 7.1% | 8,531,860 | 0 | 8,531,860 | /s/ Michael Nachmani | Michael Nachmani / Chief Operating Officer | |
| David Rosen | 7.1% | 8,531,860 | 0 | 8,531,860 | /s/ David Rosen | David Rosen, Individually |